| abstract |
In the present invention there are described arylacylaminoethanes of the general formula I, in which Ri1 represents aryl or heteroaryl, Ri2 represents hydrogen, a lower alkyl or aryl-lower alkyl, Ri3 represents hydrogen, a lower alkyl, aryl or heteroaryl, Ri4 represents aryl or heteroaryl, X represents alkylene containing 1 to 7 carbon atoms, Ci2-Ci7-alkenylene having 2 to 7 carbon atoms and Am represents an optionally substituted amino group, and their salts. These compounds are active as NK1 antagonists. In the present invention there are further described a process for preparing these compounds as well as pharmaceutical preparation in which they are comprised. |